Cardiovascular physiology

Deepening Supply Shortage Causes Homes to Spend Nearly 50% Less Time on Market, New HouseCanary Report Finds

Retrieved on: 
Thursday, May 13, 2021
Data management, Technology, Other Construction & Property, Residential Building & Real Estate, Software, Construction & Property, Cardiovascular physiology, Pulse

b'HouseCanary, Inc. (\xe2\x80\x9cHouseCanary\xe2\x80\x9d), a leading provider of residential real estate data and home valuations, today released its latest Market Pulse report, covering 22 listing-derived metrics and comparing data between April 2020 and April 2021.

Key Points: 
  • b'HouseCanary, Inc. (\xe2\x80\x9cHouseCanary\xe2\x80\x9d), a leading provider of residential real estate data and home valuations, today released its latest Market Pulse report, covering 22 listing-derived metrics and comparing data between April 2020 and April 2021.
  • The Market Pulse is an ongoing review of proprietary data and insights from HouseCanary\xe2\x80\x99s nationwide platform.\nThis press release features multimedia.
  • One year later, we are finally starting to see some positive developments on the supply side for the first time since the pandemic began.
  • New listings are up 19.1% year-over-year, however, the number of listings under contract continues to outpace the increase in new listings, which leads us to believe that the supply shortage will hold strong in the short-term.\xe2\x80\x9d\nSelect findings from this month\xe2\x80\x99s Market Pulse are below.

Study Investigates the Ability of Masimo PVi® to Predict Preload Responsiveness in Patients On Nasal High-Flow Therapy

Retrieved on: 
Monday, May 3, 2021
General Health, Pharmaceutical, Health, Medical devices, Medicine, Branches of biology, Clinical medicine, Medical monitoring, Cardiovascular physiology, Masimo, Pulse oximetry, XC2, Preload, CO-oximeter

PVi was measured using a Masimo Radical-7\xc2\xae Pulse CO-Oximeter\xc2\xae with a pulse oximetry sensor attached to the finger.

Key Points: 
  • PVi was measured using a Masimo Radical-7\xc2\xae Pulse CO-Oximeter\xc2\xae with a pulse oximetry sensor attached to the finger.
  • Preload responsiveness was defined as a \xe2\x89\xa5 10% increase in SV after PLR.
  • A fluid challenge was then conducted by administering a 250-mL saline solution to patients who were found to be preload responders (12 of the 20 patients).
  • SV/CO and PVi were measured again after the fluid challenge in these patients.\nThe researchers found that preload responders showed higher baseline PVi values and \xce\x94PVi after PLR.

OnLume Surgical Completes $7 Million Series A Financing

Retrieved on: 
Friday, April 30, 2021
Biotechnology, Health, Surgery, Medical devices, Branches of biology, Biology, Cardiovascular physiology, Perfusion, Respiratory physiology, Underwater diving physiology, Organ transplantation, Fluorescence

Bowman, OnLume\xe2\x80\x99s Chief Executive Officer.

Key Points: 
  • Bowman, OnLume\xe2\x80\x99s Chief Executive Officer.
  • The technology is cleared for fluorescence imaging of blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, reconstructive and microsurgeries.
  • Research referenced in this press release is supported by the National Cancer Institute of the National Institutes of Health under the award number R44CA206754.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429006246/en/\n"

Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)

Retrieved on: 
Thursday, April 29, 2021
Branches of biology, Blood tests, Blood, Anatomy, Cardiovascular physiology, Hematology, Intravascular volume status, Blood volume

Blood volume parameters were measured with Daxor\xe2\x80\x99s BVA-100 diagnostic blood test; a safe, accurate and objective means to directly quantify blood volume and composition.

Key Points: 
  • Blood volume parameters were measured with Daxor\xe2\x80\x99s BVA-100 diagnostic blood test; a safe, accurate and objective means to directly quantify blood volume and composition.
  • Blood volumes were expressed as a percent deviation from the patient\xe2\x80\x99s ideal volumes.\nThe results showed that the mechanism of sodium intake directly affects intravascular blood volume as measured by the BVA-100 blood test.
  • Daxor\xe2\x80\x99s BVA-100 blood test is the proven gold standard for doing so,\xe2\x80\x9d said Michael Feldschuh, CEO and President of Daxor Corporation.
  • We developed and market the BVA-100\xc2\xae (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.

The MESI mTABLET ABI has been chosen as a finalist in the Cardiovascular Devices category in the 2021 Medical Design Excellence Awards competition

Retrieved on: 
Thursday, April 29, 2021
Physical examination, Cardiovascular physiology, Ankle–brachial pressure index, Medical ultrasonography, Peripheral artery disease, Mesi, Abi, Medical device, Mesi, Device, Branches of biology, Medicine

b"LJUBLJANA, Slovenia, April 29, 2021 /PRNewswire/ -- MESI mTABLET ABI , device used for early detection of Peripheral Arterial Disease (PAD) by measuring Ankle-Brachial Index (ABI), has been announced as a finalist in the Cardiovascular Device category in the 2021 Medical Design Awards (MDEA) competition.

Key Points: 
  • b"LJUBLJANA, Slovenia, April 29, 2021 /PRNewswire/ -- MESI mTABLET ABI , device used for early detection of Peripheral Arterial Disease (PAD) by measuring Ankle-Brachial Index (ABI), has been announced as a finalist in the Cardiovascular Device category in the 2021 Medical Design Awards (MDEA) competition.
  • MESI, with their innovative MESI mTABLET ABI medical device, competes in the category of Cardiovascular Devices.
  • The winners will be announced on May 13 during the MedTech Design summit.\nMESI mTABLET ABI is the smartest wireless Ankle-Brachial Index measurement device on the market.
  • With strong in-house research & development and a certified production facility, we are a trustworthy provider of digital and connected diagnostic devices.\n"

The MESI mTABLET ABI has been chosen as a finalist in the Cardiovascular Devices category in the 2021 Medical Design Excellence Awards competition

Retrieved on: 
Thursday, April 29, 2021
Physical examination, Cardiovascular physiology, Ankle–brachial pressure index, Medical ultrasonography, Peripheral artery disease, Mesi, Abi, Medical device, Mesi, Device, Branches of biology, Medicine

b"LJUBLJANA, Slovenia, April 29, 2021 /PRNewswire/ -- MESI mTABLET ABI , device used for early detection of Peripheral Arterial Disease (PAD) by measuring Ankle-Brachial Index (ABI), has been announced as a finalist in the Cardiovascular Device category in the 2021 Medical Design Awards (MDEA) competition.

Key Points: 
  • b"LJUBLJANA, Slovenia, April 29, 2021 /PRNewswire/ -- MESI mTABLET ABI , device used for early detection of Peripheral Arterial Disease (PAD) by measuring Ankle-Brachial Index (ABI), has been announced as a finalist in the Cardiovascular Device category in the 2021 Medical Design Awards (MDEA) competition.
  • MESI, with their innovative MESI mTABLET ABI medical device, competes in the category of Cardiovascular Devices.
  • The winners will be announced on May 13 during the MedTech Design summit.\nMESI mTABLET ABI is the smartest wireless Ankle-Brachial Index measurement device on the market.
  • With strong in-house research & development and a certified production facility, we are a trustworthy provider of digital and connected diagnostic devices.\n"

PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Amines, Ayahuasca, Entheogens, Cardiovascular physiology, Neurotrauma, Reperfusion injury, N,N-Dimethyltryptamine, Cell biology, Ischemia, Oxidative stress

Firstly, PharmaDrug is already at work evaluating specific DMT formulations aimed at superior delivery and improved efficacy.

Key Points: 
  • Firstly, PharmaDrug is already at work evaluating specific DMT formulations aimed at superior delivery and improved efficacy.
  • Secondly, management will contemplate additional pre-clinical research in inflammatory and oxidative stress-induced complications, including organ transplants, to better understand the role DMT plays in the field.
  • Lastly, the Company will broaden its scope to evaluate other rare indications that potentially could benefit from DMT.\n"We are the first and only company in the world to receive FDA orphan drug designation for DMT," said Daniel Cohen, CEO of PharmaDrug.
  • Consistent with these functions, DMT was found to mitigate ischemia-reperfusion injury (IRI) caused by hypoxia, oxidative stress and inflammation in preclinical models of renal transplantation.

Quantum Genomics Will Present Top-line Results From its QUORUM Study of Firibastat in Heart Failure Post Myocardial Infarction at the European Society of Cardiology (ESC) Meeting

Retrieved on: 
Wednesday, April 21, 2021
Anatomy, Branches of biology, Aging-associated diseases, Circulatory system, Heart diseases, Cardiovascular physiology, Ejection fraction, Heart failure, Cardiology, Ventricle, Heart, Myocardial infarction

b'PARIS, April 21, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, will present top-line results from its QUORUM study of firibastat in heart failure post myocardial infarction at the European Society of Cardiology (ESC) meeting in August 2021.

Key Points: 
  • b'PARIS, April 21, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, will present top-line results from its QUORUM study of firibastat in heart failure post myocardial infarction at the European Society of Cardiology (ESC) meeting in August 2021.
  • The primary endpoint is the change from baseline in Left Ventricle Ejection Fraction (LVEF) assessed by Cardiac Magnetic Resonance (CMR) after a three-month treatment.
  • Gilles Montalescot, lead investigator of the QUORUM trial commented: \xe2\x80\x9cWe are pleased to present the results of the QUORUM study in August.
  • Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain.

Pulse Biosciences to Present Consumer Research on Patient Perceptions of Benign Lesion Clearance at American Academy of Dermatology VMX Meeting 2021

Retrieved on: 
Thursday, April 22, 2021
Health, Medical devices, Technology, Surgery, Nanotechnology, Clinical trials, Biotechnology, Cardiovascular physiology, Pulse

\xe2\x80\x9cThis study of patient perceptions reminds us that patients have their own preferences and priorities regarding treatments that are important.

Key Points: 
  • \xe2\x80\x9cThis study of patient perceptions reminds us that patients have their own preferences and priorities regarding treatments that are important.
  • Physicians and patients are invited to explore the online resource and learn more about the benefits of the CellFX procedure.
  • These statements are not historical facts but rather are based on Pulse Biosciences\xe2\x80\x99 current expectations, estimates, and projections regarding Pulse Biosciences\xe2\x80\x99 business, operations and other similar or related factors.
  • Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210422005425/en/\n'

OpSens Integrates its OptoWire's dPR and FFR Algorithms Within Cathmedical Cardiovascular's Picasso System in Spain

Retrieved on: 
Wednesday, April 21, 2021
Blood, Cardiovascular physiology, Exercise physiology, Hemodynamics

Cardiologists have already had the opportunity to appreciate independently the Picasso system and the OptoWire III for their performances, ease of use and accurate measurements.

Key Points: 
  • Cardiologists have already had the opportunity to appreciate independently the Picasso system and the OptoWire III for their performances, ease of use and accurate measurements.
  • This partnership is an example of the value OpSens can offer by combining its expertise with the one of its partners.
  • "\nAlfredo Garcia, General Manager of Cathmedical, said, "We are very pleased with this partnership with OpSens.
  • It provides our customers access to the combination of the best hemodynamic system to the best pressure guidewire system on the market.